Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Ongoing HTAs in Skåne region in Sweden in September 2023

In September 2023, the Skåne University Hospital is working on several HTAs, including evaluations in the cardiovascular, diagnostic imaging, men’s health, neurology and neurosurgery fields. Some examples can be found below:

  • Organized prostate cancer testing (health economic analysis);
  • Green laser in vaporization of prostatic hyperplasia compared to transurethral resection of the prostate;
  • Time interval for radiological follow-up after lung cancer and central nervous system tumors (mainly glioma);
  • MR-guided focused ultrasound (MRgFUS) as an alternative treatment for tremor;
  • Support to the National Knowledge Management Organization; The Southern healthcare region's National patient overview (regards care course normal pressure hydrocephalus, ALS and dental care);
  • Frequency of radiological follow-up examinations in lung cancer and central nervous system tumors.

The full details in Swedish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.